The current pandemic infection of coronavirus disease 2019 (COVID‐2019) is caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), a novel RNA β‐coronavirus, that shares 79% sequence identity with SARS‐CoV, the virus that caused a major outbreak in 2002‐2003. Usually, COVID‐19 is transmitted by inhalation or contact with infected droplets or touching surfaces contaminated by them and then touching the nose, mouth, or eyes, even if a transmission via the aerosolization/fecal‐oral route is also hypothesized.[^1^](#jcph1644-bib-0001){ref-type="ref"} The most common symptoms of patients with COVID‐19 are fever, cough, and fatigue, while other patients also have or manifest only headache, diarrhea, and lymphopenia. Chest computed tomography scans generally present as pneumonia, often with RNAemia and acute respiratory distress syndrome (ARDS) in severely ill patients. There are similarities in the symptoms between COVID‐19 and coronavirus infections, such as SARS.[^2^](#jcph1644-bib-0002){ref-type="ref"} However, COVID‐19 showed some unique clinical features, especially mainly targeting the lower airway. As of April 19, 2020, there have been more than 2.3 million reported cases and 160 000 deaths in \>200 countries. Currently, there is no evidence from randomized clinical trials to show any potential therapy improving outcomes in patients with COVID‐19.[^3^](#jcph1644-bib-0003){ref-type="ref"}

SARS‐CoV‐2 invading results in immune and inflammatory responses, even cytokine storm. Pathological observation showed that exudative inflammation occurred in the early to late phase of COVID‐19 pneumonia. Therefore, effective antiviral and potent anti‐inflammatory drugs should be administered to patients with COVID‐19 pneumonia.

In this article, we review the pathophysiology and the therapeutic agents of COVID‐19 up to now, then discuss the possible role of escin, which has shown potent anti‐inflammatory and some antiviral effects in vitro and the effects on acute lung injury in vivo, including animals and humans, in the management of acute lung injury (ALI) during COVID‐19 infection.

Pathophysiology of COVID‐19 and Therapeutic Agents {#jcph1644-sec-0020}
==================================================

COVID‐19 is characterized by pneumonia, lymphopenia, exhausted lymphocytes, and a cytokine storm (CS). Defining the immunopathological changes in patients with COVID‐19 provides potential targets for drug discovery and is important for clinical management.[^4^](#jcph1644-bib-0004){ref-type="ref"}

Pathophysiology of COVID‐19 and the Immune Response, CS {#jcph1644-sec-0030}
-------------------------------------------------------

During the viral infection, host factors trigger an immune response to be against the virus that could result in pulmonary tissue damage, functional impairment, and reduced lung capacity if the immune pathogenesis associated with an immune response is out of control.[^5^](#jcph1644-bib-0005){ref-type="ref"} In the immune response macrophages present SARS‐CoV‐2 antigens to T cells, that activate, differentiate, and release chemokines and cytokines, such as interleukin (IL)‐1, IL‐6, IL‐8, IL‐21, tumor necrosis factor (TNF)‐β, and monocyte chemotactic protein (MCP)‐1, causing the CS that recruits lymphocytes and leukocytes to the site of infection. Whether it is in an infected cell or in an immune cell, nuclear factor kappa B (NF‐κB) activation itself may play an important role in immune response and acute inflammatory lung injury (Figure [1](#jcph1644-fig-0001){ref-type="fig"}).[^5^](#jcph1644-bib-0005){ref-type="ref"}, [^6^](#jcph1644-bib-0006){ref-type="ref"}

![The immune and inflammatory responses in coronavirus infections. In the immune response, macrophages present SARS‐CoV‐2 antigens to T cells that activate, differentiate, and release chemokines and cytokines such as interleukin (IL)‐1, IL‐6, IL‐8, IL‐21, tumor necrosis factor‐β (TNF‐β), and monocyte chemotactic protein‐1 (MCP‐1), causing the cytokine storm that recruits lymphocytes and leukocytes to the site of infection. Whether it is in an infected cell or in an immune cell, nuclear factor kappa B (NF‐κB) activation itself may play an important role in immune response and acute inflammatory lung injury. ACE2, angiotensin‐converting enzyme 2; PAMPs, pathogen‐associated molecular patterns; PRRs, pattern recognition receptors; TLR4, Toll‐like receptor 4.](JCPH-9999-na-g001){#jcph1644-fig-0001}

Growing evidence suggests that a subgroup of patients with severe COVID‐19 might have a CS syndrome with systemic inflammation, multiple organ failure, and high inflammatory parameters.[^7^](#jcph1644-bib-0007){ref-type="ref"} CS has been previously documented in patients with coronavirus pneumonia infection, that is, SARS and Middle East respiratory syndrome (MERS) accompanied by rapid viral replication and inflammatory cell infiltration leading to ALI and death.[^8^](#jcph1644-bib-0008){ref-type="ref"}, [^9^](#jcph1644-bib-0009){ref-type="ref"} In a recent clinical trial in 41 COVID‐19 infected patients in Wuhan, Huang et al[^10^](#jcph1644-bib-0010){ref-type="ref"} documented high amounts of IL‐1β, interferon (IFN)‐γ, IFN‐γ--inducible protein, and MCP‐1, probably leading to activated T‐helper‐1 cell responses. Moreover, the same authors documented higher concentrations of granulocyte colony‐stimulating factor, IFN‐γ--inducible protein, MCP‐1, macrophage inflammatory protein 1α, and TNF‐α in intensive care unit hospitalized SARS‐CoV‐2--infected patients than did those not requiring intensive care unit admission, suggesting that CS was associated with disease severity.[^10^](#jcph1644-bib-0010){ref-type="ref"} Finally, several studies documented a significant increase in IL‐6 plasma levels in critically ill patients with COVID‐19.[^11^](#jcph1644-bib-0011){ref-type="ref"}, [^12^](#jcph1644-bib-0012){ref-type="ref"}, [^13^](#jcph1644-bib-0013){ref-type="ref"}, [^14^](#jcph1644-bib-0014){ref-type="ref"} This increase in CS is associated with ALI during COVID‐19 infection, and it is characterized by an in intra‐alveolar fibrin accumulation that stimulates the production of both profibrotic growth factors[^15^](#jcph1644-bib-0015){ref-type="ref"} and profibrotic cytokine transcripts, such as transforming growth factor‐β, connective tissue growth factor, and platelet‐derived growth factor, with a decrease in pulmonary surfactant protein, leading to collapse or closure of alveoli and loss of lung compliance (changes in lung volumes).[^16^](#jcph1644-bib-0016){ref-type="ref"} In combination, a high‐fibrin/low‐surfactant intra‐alveolar environment provides an ideal environment for fibroblast adherence and growth, resulting in collagen deposition and development of lung fibrosis.[^17^](#jcph1644-bib-0017){ref-type="ref"} Finally, fibrin and fibrin breakdown products increase vascular permeability, stimulate migration and proliferation of inflammatory cells, and promote recruitment of neutrophils to the lung.[^18^](#jcph1644-bib-0018){ref-type="ref"}, [^19^](#jcph1644-bib-0019){ref-type="ref"} Taken together, these factors decrease the capacity to cleave and remove fibrin deposits corresponding with a poor clinical patient outcome.[^20^](#jcph1644-bib-0020){ref-type="ref"} Moreover, the increased release of proinflammatory factors (IL‐1, IL‐6, IL‐8, IL‐21, TNF‐β, and MCP‐1, etc) is associated with hypercoagulation and disseminated intravascular coagulation, that could induce an impairment in clinical conditions. Additionally, the subgroup of patients having immunosuppression could improve mortality; therefore, it is of great significance to pay attention to sepsis immunosuppression caused by COVID‐19.[^21^](#jcph1644-bib-0021){ref-type="ref"}, [^22^](#jcph1644-bib-0022){ref-type="ref"}, [^23^](#jcph1644-bib-0023){ref-type="ref"}

Pathological Changes of Lungs in Patients With COVID‐19 {#jcph1644-sec-0040}
-------------------------------------------------------

Tian et al[^24^](#jcph1644-bib-0024){ref-type="ref"} described 2 patients who underwent lung lobectomies for adenocarcinoma (pT1bN0) and were later found to have been infected with SARS‐CoV‐2. Pathological findings from these 2 patients are edema and prominent proteinaceous exudates, vascular congestion, and inflammatory clusters with fibrinoid material and multinucleated giant cells.[^24^](#jcph1644-bib-0024){ref-type="ref"} Liu et al[^25^](#jcph1644-bib-0025){ref-type="ref"} and Xu et al[^26^](#jcph1644-bib-0026){ref-type="ref"} found that the pathological features of COVID‐19 resemble those exhibited in MERS and SARS. In particular, during the autopsy of a COVID‐19 cadaver, Liu et al[^25^](#jcph1644-bib-0025){ref-type="ref"} documented in right pleura the presence of an intense inflammation, with edema and fiber bands. Similarly, histologic examination performed by Xu et al[^26^](#jcph1644-bib-0026){ref-type="ref"} showed bilateral diffuse alveolar damage with cellular fibromyxoid exudates and interstitial mononuclear inflammatory infiltrates. Using minimally invasive autopsies in 3 patients died from COVID‐19 pneumonia, Yao et al[^27^](#jcph1644-bib-0027){ref-type="ref"} described alveolar exudative inflammation and interstitial inflammation, alveolar epithelium proliferation and hyaline membrane formation. All findings above suggest that exudative inflammation occurred in the early to late phase of COVID‐19 pneumonia. Therefore, potent anti‐inflammatory drugs should be administered for COVID‐19 pneumonia besides antiviral drugs.

Based on the pathophysiology and pathological changes of lungs in patients with COVID‐19, it may be better for them if antiviral and anti‐inflammatory drugs are administered early. In the late stage, uncontrolled pulmonary inflammation caused by SARS‐CoV‐2 infection will lead to CS, immunosuppression, and ARDS, and it may be difficult to attenuate the severe ALI with any management.

Drug Treatment for COVID‐19 {#jcph1644-sec-0050}
===========================

Antiviral Treatment of COVID‐19 {#jcph1644-sec-0060}
-------------------------------

To date, there is not a specific treatment for COVID‐19,[^28^](#jcph1644-bib-0028){ref-type="ref"}, [^29^](#jcph1644-bib-0029){ref-type="ref"} even if some clinical trials are ongoing to evaluate their effects as add‐on therapy in COVID‐19 patients. Drugs possibly effective for COVID‐19 are reported in Table [1](#jcph1644-tbl-0001){ref-type="table"}. Lopinavir‐ritonavir and add‐on IFNα‐1b has been studied for MERS treatment,[^30^](#jcph1644-bib-0030){ref-type="ref"}, [^31^](#jcph1644-bib-0031){ref-type="ref"} and in recent clinical trials it has been also proposed for COVID‐19 treatment.[^14^](#jcph1644-bib-0014){ref-type="ref"}, [^32^](#jcph1644-bib-0032){ref-type="ref"} However, Cao et al,[^33^](#jcph1644-bib-0033){ref-type="ref"} in a randomized, controlled, open‐label trial in 199 hospitalized adult patients with COVID‐19, documented that the lopinavir‐ritonavir combination (400 mg and 100 mg, respectively, twice daily for 14 days) was not associated with clinical improvement compared with standard care procedures. In a recent retrospective cohort study in COVID‐19 patients, Deng et al[^34^](#jcph1644-bib-0034){ref-type="ref"} documented that a 14‐day treatment with lopinavir‐umifenovir (also called arbidol) induced a significant improvement (*P* \< .05) of clinical symptoms and laboratory finding (virus detection), compared to lopinavir alone. Favipiravir, a purine nucleic acid analog (Table [1](#jcph1644-tbl-0001){ref-type="table"}) approved for use in influenza, is studied in the management of COVID‐19.[^35^](#jcph1644-bib-0035){ref-type="ref"} In particular, to date (April 14, 2020), 9 clinical trials have been recorded in the World Health Organization database: 7 favipiravir alone (JPRN‐jRCTs041190120, JPRN‐jRCTs031190226, ChiCTR2000030254, ChiCTR2000030113, ChiCTR2000029600, ChiCTR2000029548, ChiCTR2000029544), 1 plus chloroquine phosphate (ChiCTR2000030987), and 1 plus tocilizumab (ChiCTR2000030894).

###### 

Antiviral Drugs Used to Treat COVID‐19--Infected Patients

+------------------------------------+-------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------+---------------------------------------------------------------------------------------------------------+
| Drug                               | Anti‐infective Mechanism                                                                                          | Dosage/Duration                                                                                                                                                               | Route of Administration | NCT in WHO                                                                                              |
+:===================================+:==================================================================================================================+:==============================================================================================================================================================================+:=======================:+:=======================================================================================================:+
| Lopinavir/ritonavir                | Inhibition of HIV‐1 protease for protein cleavage                                                                 | 200 mg/100 mg, 2 tablets per day, every 12 hours for 7‐10 days                                                                                                                | Oral                    | NCT01700790                                                                                             |
+------------------------------------+-------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------+---------------------------------------------------------------------------------------------------------+
|                                    |                                                                                                                   | Not indicated                                                                                                                                                                 | Oral                    | ChiCTR2000029603                                                                                        |
+------------------------------------+-------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------+---------------------------------------------------------------------------------------------------------+
| Favipiravir                        | Acting on viral genetic copying to prevent its reproduction, without affecting host cellular RNA or DNA synthesis | Not indicated                                                                                                                                                                 | Oral                    | ChiCTR2000030254                                                                                        |
|                                    |                                                                                                                   |                                                                                                                                                                               |                         |                                                                                                         |
|                                    |                                                                                                                   |                                                                                                                                                                               |                         | ChiCTR2000029600                                                                                        |
+------------------------------------+-------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------+---------------------------------------------------------------------------------------------------------+
|                                    |                                                                                                                   | On the first day, 1600 mg each time, twice a day; from the second to the seventh day, 600 mg each time, twice a day; the maximum number of days taken is not more than 7 days | Oral                    | NCT04310228                                                                                             |
+------------------------------------+-------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------+---------------------------------------------------------------------------------------------------------+
|                                    |                                                                                                                   | Day 1: 1800 mg twice daily; Day 2 and thereafter: 600 mg 3 times daily, for a maximum of 14 days                                                                              | Oral                    | NCT04336904                                                                                             |
+------------------------------------+-------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------+---------------------------------------------------------------------------------------------------------+
| Chloroquine and hydroxychloroquine | Increase of endosomal pH, immunomodulation, autophagy inhibitors                                                  | 600 mg daily for 7 days                                                                                                                                                       | Oral                    | NCT04340544                                                                                             |
+------------------------------------+-------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------+---------------------------------------------------------------------------------------------------------+
|                                    |                                                                                                                   | First dose: 800 mg; from second day on, each patient will get 600 mg once a day until day 7                                                                                   | Oral                    | NCT04342221                                                                                             |
+------------------------------------+-------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------+---------------------------------------------------------------------------------------------------------+
|                                    |                                                                                                                   | Not indicated                                                                                                                                                                 | Oral                    | ChiCTR2000031782                                                                                        |
|                                    |                                                                                                                   |                                                                                                                                                                               |                         |                                                                                                         |
|                                    |                                                                                                                   |                                                                                                                                                                               |                         | ChiCTR2000030054                                                                                        |
+------------------------------------+-------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------+---------------------------------------------------------------------------------------------------------+
| Umifenovir (Arbidol)               | Inhibitor of viral fusion with the targeted membrane                                                              | 200 mg, 3 times a day for 14 days                                                                                                                                             | Oral                    | ChiCTR2000029621 ChiCTR2000029759 ChiCTR2000029592 ChiCTR1900028586 NCT04252885 NCT04246242 NCT04260594 |
+------------------------------------+-------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------+---------------------------------------------------------------------------------------------------------+
| Remdesivir                         | RNA polymerase inhibitor                                                                                          | Day 1: 200 mg; Day 2 and thereafter: 100 mg every 24 h. Available as 5‐mg/mL vial (reconstituted)                                                                             | Intravenous             | NCT04292899                                                                                             |
|                                    |                                                                                                                   |                                                                                                                                                                               |                         |                                                                                                         |
|                                    |                                                                                                                   |                                                                                                                                                                               |                         | NCT04292730                                                                                             |
|                                    |                                                                                                                   |                                                                                                                                                                               |                         |                                                                                                         |
|                                    |                                                                                                                   |                                                                                                                                                                               |                         | NCT04257656 NCT04252664 NCT04280705                                                                     |
+------------------------------------+-------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------+---------------------------------------------------------------------------------------------------------+
| Lianhuaqingwen Capsule             | Inhibitor of viral replication,                                                                                   | Routine treatment + Lianhuaqingwen Capsules; 4 capsules/time or 1 bag/time, 3 times a day                                                                                     | Oral                    | ChiCTR2000029434 ChiCTR2000029433                                                                       |
+------------------------------------+-------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------+---------------------------------------------------------------------------------------------------------+

NCT, national clinical trial number; WHO, World Health Organization.
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Wang et al[^36^](#jcph1644-bib-0036){ref-type="ref"} suggest that chloroquine and hydroxychloroquine, used in the prevention and treatment of malaria,[^37^](#jcph1644-bib-0037){ref-type="ref"} could play a role in the management of COVID‐19, due to their mechanism of action (Table [1](#jcph1644-tbl-0001){ref-type="table"}).[^38^](#jcph1644-bib-0038){ref-type="ref"}, [^39^](#jcph1644-bib-0039){ref-type="ref"}, [^40^](#jcph1644-bib-0040){ref-type="ref"} However, the problem of chloroquine is its safety related to the dosage; in fact, as suggested by Duan et al,[^41^](#jcph1644-bib-0041){ref-type="ref"} the dosage for COVID‐19 treatment is 500  mg twice daily for no more than 10 days, which is larger than of the dosage for previous treatment of malaria, so it is very important to evaluate the development of adverse reactions. In a small group of patients with COVID‐19 (n = 20), Guatret et al[^42^](#jcph1644-bib-0042){ref-type="ref"} demonstrated a significant viral load decrease, 3 days after the beginning of hydroxychloroquine plus azithromycin treatment respect to the control group (57.1% and 12.5%, respectively). However, the use of either chloroquine or hydroxychloroquine plus azithromycin for COVID‐19 infection is only supported by in vitro data and weak studies, and physicians should consider the development of adverse effects to determine their benefit, if any, in treating or preventing COVID‐19.[^43^](#jcph1644-bib-0043){ref-type="ref"}

Remdesivir is a monophosphate prodrug that undergoes metabolism to an active C‐adenosine nucleoside triphosphate analogue. Currently, remdesivir is a promising potential therapy for COVID‐19 due to its broad‐spectrum, potent in vitro activity against several novel coronaviruses, including SARS‐CoV‐2 with half maximal effective concentration and concentration for 90% of maximal effect (EC90) values of 0.77 µM and 1.76 µM, respectively. Clinical trials are ongoing to evaluate the safety and antiviral activity of remdesivir in patients with mild to moderate or severe COVID‐19.[^3^](#jcph1644-bib-0003){ref-type="ref"} Notably, Williamson et al[^44^](#jcph1644-bib-0044){ref-type="ref"} recently used the Rhesus macaque model of SARS‐CoV‐2 infection to investigate the antiviral activity of remdesivir. Therapeutic remdesivir treatment initiated early during infection has a clear clinical benefit in SARS‐CoV‐2--infected Rhesus macaques. These data support early remdesivir treatment initiation in COVID‐19 patients to prevent progression to severe pneumonia.[^44^](#jcph1644-bib-0044){ref-type="ref"}

Moreover, recently, Chen et al[^45^](#jcph1644-bib-0045){ref-type="ref"} reported that the viral genome of COVID‐19 encodes \>20 proteins; among these, two proteases (PLpro and 3CLpro) are vital to virus replication, and they suggested that sofosbuvir in the fixed combination with velpatasvir or ledipasvir could be effective in the treatment of COVID‐19 owing to their dual inhibitory actions on 2 viral enzymes. Other antiviral drugs, umifenovir, oseltamivir, and ribavirin currently are also being tested in ongoing randomized trials.[^3^](#jcph1644-bib-0003){ref-type="ref"}

Drugs Treatment for ALI of COVID‐19 With Anti‐inflammatory Mechanisms {#jcph1644-sec-0070}
---------------------------------------------------------------------

In this concern, several drugs could be used as add‐on therapy to inhibit lung inflammation and reduce CS. Azithromycin, commonly used to treat bacterial infections, could be used as add‐on antiviral therapy in patients with SARS‐CoV‐2 infection,[^28^](#jcph1644-bib-0028){ref-type="ref"} due to its immunomodulant effect.[^46^](#jcph1644-bib-0046){ref-type="ref"} In fact, to date (April 14, 2020), there are 21 clinical trials recorded on clinicaltrial.gov that evaluate the effect of azithromycin add‐on to hydroxychloroquine sulfate or tocilizumab in the treatment of hospitalized patients with moderate or severe COVID‐19. One prospective trial that is in recruiting in Utah (NCT04334382) evaluates the effect of oral azithromycin (500 mg on day 1, then 250 mg on days 2‐5) vs oral hydroxychloroquine (400 mg twice daily on day 1, then 200 mg twice daily on days 2‐4) in outpatients \>45 years old with COVID‐19. Recently, it has been reported that tocilizumab (recombinant human IL‐6 monoclonal antibody used for rheumatic diseases), to block IL‐6 signaling and its mediated inflammatory response, is approved to treat the cytokine release syndrome caused by chimeric antigen receptor T‐cell immunotherapy.[^47^](#jcph1644-bib-0047){ref-type="ref"}, [^48^](#jcph1644-bib-0048){ref-type="ref"} Until now (April 14, 2020), several clinical trials have been registered on safety and efficacy of tocilizumab (8 mg/kg intravenously, single infusion up to a maximum of 800 mg/dose) alone or with other drugs in the treatment of severe COVID‐19 pneumonia in both China registry (ChiCTR2000029765, ChiCTR2000030796, ChiCTR2000030442, and ChiCTR2000030894) and clinicaltrial.gov registry (16 trials up to April 14, 2020). Concerning the similar mechanism of action, other monoclonal antibodies or small‐molecule inhibitors are under investigation to evaluate their efficacy and safety in COVID‐19 (Table [2](#jcph1644-tbl-0002){ref-type="table"}).

###### 

Immunomodulatory Drugs Studied for COVID‐19 and Recorded in Identified at Clinicaltrials.gov up to April 14, 2020

+---------------+---------------------+--------------------------------------------------+-------------------------+----------------------------------------------------------+--------------------------+
| Drug          | Mechanism of Action | Dosage/Duration                                  | Route of Administration | Comparator                                               | NCT in WHO               |
+:==============+:====================+:=================================================+:=======================:+:=========================================================+:========================:+
| Bevacizumab   | Anti‐VEGF           | 7.5 mg/kg + 0.9% NaCl 100 mL                     | Intravenous             | None                                                     | NCT04305106              |
+---------------+---------------------+--------------------------------------------------+-------------------------+----------------------------------------------------------+--------------------------+
|               |                     | 500 mg + saline 100 mL, intravenous drip ≥90 min | Intravenous             | None                                                     | NCT04275414              |
+---------------+---------------------+--------------------------------------------------+-------------------------+----------------------------------------------------------+--------------------------+
| Anakinra      | Anti IL‐1           | 200 mg 3 times daily for 7 days                  | Intravenous             | Tocilizumab                                              | NCT04339712              |
+---------------+---------------------+--------------------------------------------------+-------------------------+----------------------------------------------------------+--------------------------+
| Situximab     |                     | 11 mg/kg, single infusion                        | Intravenous             | Placebo                                                  | NCT04330638              |
|               |                     |                                                  |                         |                                                          |                          |
|               |                     |                                                  |                         | Anakinra 100 mg for 28 days                              |                          |
|               |                     |                                                  |                         |                                                          |                          |
|               |                     |                                                  |                         | Anakinra + Siltuximab                                    |                          |
|               |                     |                                                  |                         |                                                          |                          |
|               |                     |                                                  |                         | Tocilizumab                                              |                          |
|               |                     |                                                  |                         |                                                          |                          |
|               |                     |                                                  |                         | Anakinra + Tocilizumab                                   |                          |
+---------------+---------------------+--------------------------------------------------+-------------------------+----------------------------------------------------------+--------------------------+
| Sarilumab     | Anti IL‐6           | High dose                                        | Intravenous             | Placebo                                                  | NCT04315298; NCT04327388 |
|               |                     |                                                  |                         |                                                          |                          |
|               |                     |                                                  |                         | Sarilumab low dose i.v.                                  |                          |
+---------------+---------------------+--------------------------------------------------+-------------------------+----------------------------------------------------------+--------------------------+
|               |                     | 400 mg                                           | Intravenous             | None                                                     |                          |
+---------------+---------------------+--------------------------------------------------+-------------------------+----------------------------------------------------------+--------------------------+
| Baricitinib   | JAK inhibitors      | 2 mg for 14 days                                 | Oral                    | None                                                     | NCT04340232              |
+---------------+---------------------+--------------------------------------------------+-------------------------+----------------------------------------------------------+--------------------------+
|               |                     | 2 mg for 10 days                                 | Oral                    | Lopinavir/ritonavir 200 mg/50 mg twice daily for 10 days | NCT04321993              |
|               |                     |                                                  |                         |                                                          |                          |
|               |                     |                                                  |                         | Hydroxychloroquine 200 mg twice daily for 10 days        |                          |
|               |                     |                                                  |                         |                                                          |                          |
|               |                     |                                                  |                         | Sarilumab 200 mg subcutaneously single infusion          |                          |
+---------------+---------------------+--------------------------------------------------+-------------------------+----------------------------------------------------------+--------------------------+
|               |                     | 4 mg/day for 14 days                             | Oral                    | Add‐on ritonavir 600 mg twice daily                      | NCT04320277              |
+---------------+---------------------+--------------------------------------------------+-------------------------+----------------------------------------------------------+--------------------------+
| Pembrolizumab | Anti PD‐1           | 200 mg, single dose.                             | Intravenous             | Tocilizumab                                              | NCT04335305              |
+---------------+---------------------+--------------------------------------------------+-------------------------+----------------------------------------------------------+--------------------------+
| Nivolumab     | Anti PD‐1           | 0.3 mg/kg, single infusion                       | Intravenous             | Tocilizumab                                              | NCT04333914              |
+---------------+---------------------+--------------------------------------------------+-------------------------+----------------------------------------------------------+--------------------------+
| RH‐ACE2       | Anti ACE2           | Not indicated, bid                               | Intravenous             | Placebo                                                  | NCT04335136              |
+---------------+---------------------+--------------------------------------------------+-------------------------+----------------------------------------------------------+--------------------------+

ACE2, angiotensin‐converting enzyme 2; IL, interleukin; NCT, national clinical trial number; RhACE2, recombinant human angiotensin‐converting enzyme 2; VEGF, vascular endothelial growth factor; WHO, World Health Organization.
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SARS‐CoV‐2 is able to invade and enter cells using angiotensin‐converting enzyme 2 receptor through endocytosis, which is regulated by adaptor‐associated protein kinase 1. Angiotensin‐converting enzyme 2 receptor is a cell‐surface protein widely existed on cells in the heart, kidney, blood vessels, especially lung alveolar epithelium type 2 cells.[^49^](#jcph1644-bib-0049){ref-type="ref"}, [^50^](#jcph1644-bib-0050){ref-type="ref"}, [^51^](#jcph1644-bib-0051){ref-type="ref"} Considering this mechanism, drugs able to block adaptor‐associated protein kinase 1 (eg, sarilumab and baricitinib) can interrupt both the passage of the virus into cells and the cytokine storm and could be used in COVID‐19 treatment.[^52^](#jcph1644-bib-0052){ref-type="ref"}

Metronidazole, decreasing the levels of proinflammatory cytokines, (ie, IL‐1α and β, IL‐6, IL‐8, IL‐12, IFN‐γ, TNF‐α) as well as the levels of C‐reactive protein and neutrophil count, could be efficacious in the management of immunopathological manifestations of the COVID‐19[^53^](#jcph1644-bib-0053){ref-type="ref"}; however, clinical studies must be performed to further validate this experimental observation.

Concerning the role of corticosteroids as add‐on therapy in COVID‐19 patients, even if they have anti‐inflammatory and immunomodulatory activity,[^54^](#jcph1644-bib-0054){ref-type="ref"}, [^55^](#jcph1644-bib-0055){ref-type="ref"}, [^56^](#jcph1644-bib-0056){ref-type="ref"} to date, there is no evidence concerning their efficacy to improve the clinical outcomes in these patients.[^57^](#jcph1644-bib-0057){ref-type="ref"}, [^58^](#jcph1644-bib-0058){ref-type="ref"} Moreover, corticosteroids can delay the viral clearance[^59^](#jcph1644-bib-0059){ref-type="ref"}, [^60^](#jcph1644-bib-0060){ref-type="ref"}, [^61^](#jcph1644-bib-0061){ref-type="ref"}; therefore, Arabi et al[^61^](#jcph1644-bib-0061){ref-type="ref"} advise against their continuous use in SARS‐CoV‐2--infected patients. In addition, in the late stage of COVID‐19, immunosuppression can often be seen in patients; therefore, the use of corticosteroids may aggravate this condition in patients with COVID‐19.[^4^](#jcph1644-bib-0004){ref-type="ref"} In agreement with these data, the guideline of the World Health Organization[^62^](#jcph1644-bib-0062){ref-type="ref"} does not suggest the use of systemic corticosteroids for the treatment of viral pneumonia and ARDS for suspected COVID‐19 cases.

Finally, some natural products and traditional medicines are investigated to treat patients with COVID‐19. Lianhuaqingwen Capsule, a traditional Chinese medicine formula, has been used to treat influenza and exerted broad‐spectrum antiviral effects on a series of influenza viruses and immune regulatory effects.[^63^](#jcph1644-bib-0063){ref-type="ref"} Recently, Lianhuaqingwen Capsule has been registered in clinical center of China (ChiCTR2000029434, ChiCTR2000029433) to treat patients with COVID‐19 pneumonia (Table [1](#jcph1644-tbl-0001){ref-type="table"}) and was finally approved (Approval No. 2020B02813) by the National Medical Products Administration of China for the treatment of mild and moderate coronavirus pneumonia on April 12, 2020.

Escin represents some isomers of escin saponins or the natural mixture of triterpene saponins in different production extracted from seeds of *Aesculus hippocastanum* L., *Aesculus wilsonii* Rehd, and others. In China, sodium aescinate injection consists of A, B, C, and D escin, of which A and B are the main components that belong to β‐escin (Figure [2](#jcph1644-fig-0002){ref-type="fig"}). Accumulating evidence suggests that escin exerts potent anti‐inflammatory, anti‐edematous effects and has been used to treat acute edema in clinic. Recently, the sodium of escin, sodium aescinate injection, was registered in the clinical center of China (ChiCTR2000029742) and Italy (NCT04322344) to treat patients with COVID‐19 pneumonia.

![Chemical structure of escin. Escin is a natural mixture of triterpene saponins extracted from seeds of *Aesculus hippocastanum*. It mainly consists of A, B, C, and D escin, of which A and B are the main components that belong to β‐escin.](JCPH-9999-na-g002){#jcph1644-fig-0002}

Anti‐inflammatory, Antiviral Effects of Escin In Vitro and Its Effects on ALI {#jcph1644-sec-0080}
=============================================================================

Anti‐inflammatory Effects of Escin In Vitro {#jcph1644-sec-0090}
-------------------------------------------

Xin et al[^64^](#jcph1644-bib-0064){ref-type="ref"} reported that 10 µg/mL of escin significantly inhibits the secretion of inflammatory factors including nitric oxide (NO), TNF‐α, and IL‐1β in lipopolysaccharide (LPS)‐stimulated RAW264.7 macrophage cells. Furthermore, the combination of suboptimal concentrations of 0.1 µg/mL of escin with 1 ng/mL of corticosterone, which alone could not depress the release of inflammatory factors, inhibited the secretion of NO, TNF‐α, and IL‐1β in vitro. These findings suggest that escin can synergize with glucocorticoids to enhance their anti‐inflammatory effect. In human endothelial cells under inflammatory conditions, β‐escin (3 µM) inhibits the inflammation blocking nuclear translocation of p50 and p65.[^65^](#jcph1644-bib-0065){ref-type="ref"} Montopoli et al[^66^](#jcph1644-bib-0066){ref-type="ref"} reported that escin shows dose‐dependent (0.1‐1 µM) effects in LPS‐activated endothelial cells, reducing IL‐6 release and vascular cell adhesion molecule‐1 activity. In another experimental study in human endothelial cells, Chen et al^67^ documented that escin (10 µg/mL) inhibits the overexpression of the aquaporin‐1 and alleviates barrier dysfunction induced by proinflammatory high mobility group protein 1.

Antiviral Effects of Escin In Vitro {#jcph1644-sec-0100}
-----------------------------------

Escin shows antiviral activities against SARS‐CoV, respiratory syncytial virus (RSV), and some other viruses (Table [3](#jcph1644-tbl-0003){ref-type="table"}). In SARS‐CoV‐infected Vero E6 cells, the half maximal effective concentration for escin against SARS‐CoV was 6 µM.[^68^](#jcph1644-bib-0068){ref-type="ref"} RSV infection is the leading cause of acute respiratory tract infections in childhood. In RSV‐infected epithelial and macrophage cell lines, 5 µg/mL of escin and 25 µg/mL of *Aesculus hippocastanum* seed extract show significant virucidal and antiviral activities against RSV by modulating activities of NF‐κB, activator protein‐1, and cytokine.[^69^](#jcph1644-bib-0069){ref-type="ref"} In addition, herpes simplex virus‐1, vesicular stomatitis virus, and dengue virus are also inhibited by escin and seed extract in vitro. In agreement, Michelini et al[^70^](#jcph1644-bib-0070){ref-type="ref"} reported that both escin and seed extract decrease levels of TNF‐α and IL‐6 in J774A.1 cells infected with HSV‐1 or stimulated with Toll‐like receptor ligands, probably through the inhibition of NF‐κB and activator protein‐1 signaling pathways. These results support the use of escin in COVID‐19 pneumonia because escin has potent anti‐inflammatory activities by inhibiting inflammatory cytokines such as IL‐6, TNF‐α, and IL‐1β, and shows antiviral activity on SARS‐CoV, RSV, dengue virus, and others.

###### 

Antiviral Effect of Escin

+---------+---------------+---------------------+------------+------------+--------------------------------------------+
| Escin   | Target Virus  | Virucidal/Antiviral | EC~50~     | Cell Model | Ref.                                       |
+:========+:=============:+:===================:+:===========+:==========:+:==========================================:+
| β‐escin | SARS‐CoV      | Antiviral           | 6 µM       | Vero E6    | [^68^](#jcph1644-bib-0068){ref-type="ref"} |
+---------+---------------+---------------------+------------+------------+--------------------------------------------+
| β‐escin | RSV           | Antiviral           | 1.6 µg/mL  | HEp‐2      | [^69^](#jcph1644-bib-0069){ref-type="ref"} |
|         |               |                     |            |            |                                            |
|         |               |                     | 2.4 µg/mL  | A549       |                                            |
|         |               |                     |            |            |                                            |
|         |               |                     | 1.5 µg/mL  | Vero       |                                            |
+---------+---------------+---------------------+------------+------------+--------------------------------------------+
|         |               | Virucidal           | 14.5 µg/mL | ...        |                                            |
+---------+---------------+---------------------+------------+------------+--------------------------------------------+
|         | RSV A2        | Antiviral           | 1.4 µg/mL  | HEp‐2      |                                            |
|         |               |                     |            |            |                                            |
|         |               |                     | 1.8 µg/mL  | A549       |                                            |
|         |               |                     |            |            |                                            |
|         |               |                     | 2.6 µg/mL  | Vero       |                                            |
+---------+---------------+---------------------+------------+------------+--------------------------------------------+
|         |               | Virucidal           | 15.1 µg/mL | ...        |                                            |
+---------+---------------+---------------------+------------+------------+--------------------------------------------+
| β‐escin | HSV‐1         | Antiviral           | 1.5 µg/ml  | HCLE       | [^70^](#jcph1644-bib-0070){ref-type="ref"} |
|         |               |                     |            |            |                                            |
|         |               |                     | 2.4 µg/mL  | NHC        |                                            |
|         |               |                     |            |            |                                            |
|         |               |                     | 1.9 µg/mL  | Vero       |                                            |
+---------+---------------+---------------------+------------+------------+--------------------------------------------+
|         |               | Virucidal           | 15.9 µg/mL | ...        |                                            |
+---------+---------------+---------------------+------------+------------+--------------------------------------------+
|         | VSV           | Antiviral           | 10 µg/mL   | Vero       |                                            |
+---------+---------------+---------------------+------------+------------+--------------------------------------------+
|         | Dengue type 2 |                     | (dose)     |            |                                            |
+---------+---------------+---------------------+------------+------------+--------------------------------------------+

A549, human lung carcinoma cell line; EC~50~, half maximal effective concentration; HCLE, human corneal cells; HEp‐2, human epidermoid cancer cell line; HSV, herpes simplex virus; NHC, human conjunctival cells; RSV, respiratory syncytial virus; VSV, vesicular stomatitis virus.
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Effects of Escin on ALI In Vivo {#jcph1644-sec-0110}
-------------------------------

Several authors described the effects of escin on ALI in animal models. In particular, Wang et al[^71^](#jcph1644-bib-0071){ref-type="ref"} reported that β‐escin reduces the degree of lung injury and improves function of gas exchange in LPS‐induced lung inflammation in mice by inhibiting both the lipid peroxidation and the expression of proinflammatory factors, for example, NO, TNF‐α, IL‐1β, and IL‐6. Further, Xin et al[^72^](#jcph1644-bib-0072){ref-type="ref"} described that escin could increase glucocorticoid receptor in the lung of animals, especially reversing the decrease of glucocorticoid receptor resulting from LPS, supporting the idea that the anti‐inflammatory effect of escin could involve the upregulation of glucocorticoid receptor with an increase of endogenous antioxidant activity. In a mouse model of pneumococcal pneumonia, a 4‐day administration of escin (1.8 mg/kg intravenously), significantly reduced lung inflammation, suggesting a role for escin as add‐on treatment.[^73^](#jcph1644-bib-0073){ref-type="ref"}, [^74^](#jcph1644-bib-0074){ref-type="ref"}

Finally, several authors reported that escin is able to attenuate nonpathogenic lung injury. In rats with ALI induced by phosgene (Psg), which is used extensively in industry, escin injection decreased the mortality of animals.[^74^](#jcph1644-bib-0074){ref-type="ref"} In an experimental model of ALI induced by oleic acid injection (0.1 mL/kg intravenously), Wei et al[^75^](#jcph1644-bib-0075){ref-type="ref"} documented that both pretreatment (1 mg/kg) and treatment (1‐6 mg/kg) with sodium aescinate reduces oleic acid--induced ALI by modulating the levels of superoxide dismutase, malondialdehyde and matrix metallopeptidase 9 in plasma and lung tissue. These results have been confirmed by Huang et al[^76^](#jcph1644-bib-0076){ref-type="ref"}; experimental models of oleic acid--induced pulmonary fibrosis showed that sodium aescinate improves lung fibrosis by inhibiting the levels of proinflammatory factors, such as IL‐1β, TNF‐α, and transforming growth factor‐β1.

Clinical Studies on Escin {#jcph1644-sec-0120}
-------------------------

The clinical efficacy of escin, administered for 6 to 20 days, on respiratory diseases has been reported (Table [4](#jcph1644-tbl-0004){ref-type="table"}). Xiao[^77^](#jcph1644-bib-0077){ref-type="ref"} documented that the injection of sodium aescinate in SARS‐infected patients has anti‐inflammatory and antiexudative effects and reduces the adverse drug reaction related to glucocorticoid administration. Other authors reported the effects of escin on acute pulmonary edema in patients with thoracic trauma,[^78^](#jcph1644-bib-0078){ref-type="ref"}, [^79^](#jcph1644-bib-0079){ref-type="ref"}, [^80^](#jcph1644-bib-0080){ref-type="ref"} radiation pneumonitis,[^81^](#jcph1644-bib-0081){ref-type="ref"} thoracotomy,[^82^](#jcph1644-bib-0082){ref-type="ref"} and pneumonia.[^83^](#jcph1644-bib-0083){ref-type="ref"} Finally, escin improves pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease and chronic pulmonary heart disease through the inhibition of cytokine release.[^84^](#jcph1644-bib-0084){ref-type="ref"}, [^85^](#jcph1644-bib-0085){ref-type="ref"}, [^86^](#jcph1644-bib-0086){ref-type="ref"}, [^87^](#jcph1644-bib-0087){ref-type="ref"}

###### 

Roles of Escin Administered Intravenously in Human Lung Injury

  Escin                 Dosage/Duration  Diseases                          Biomarkers Used for Assessment of Efficacy                                                                                                                       Ref.
  -------------------- ----------------- --------------------------------- ---------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------
  Sodium aescinate       20 mg/d; 10 d   SARS                              Reducing inflammatory exudation in the lung                                                                                                   [^77^](#jcph1644-bib-0077){ref-type="ref"}
  Aescine                20 mg/d; 6 d    Traumatic acute lung injury       Inhibiting TNF‐α, IL‐1, IL‐6, IL‐8 in serum; improving pulmonary function including PaO~2~, PaCO~2~, PaO~2~/FiO~2~                            [^77^](#jcph1644-bib-0077){ref-type="ref"}
  β‐sodium aescinate    0.4 mg/kg; 7 d   Traumatic acute lung injury       Improving pulmonary function including SpO~2~, PaO~2~, PaCO~2~, PaO~2~/FiO~2~, FEV~1~, FVC, PEF, MMEF                                         [^79^](#jcph1644-bib-0079){ref-type="ref"}
  β‐sodium aescinate     20 mg/d; 14 d   Pulmonary contusion               Reducing the incidence of pulmonary infection, ARDS, and mortality                                                                            [^80^](#jcph1644-bib-0080){ref-type="ref"}
  β‐sodium aescinate     20 mg/d; 20 d   Acute radiation pneumonitis       Reducing the incidence of radiation‐induced lung injury; improving pulmonary function including PaO~2~, MVV, FEV/FVC                          [^81^](#jcph1644-bib-0081){ref-type="ref"}
  Sodium aescinate       20 mg/d; 12 d   Thoracotomy                       Reducing pleural effusion                                                                                                                     [^82^](#jcph1644-bib-0082){ref-type="ref"}
  Sodium aescinate       10 mg/d; 10 d   Pneumonia‐like pleural effusion   Reducing pleural effusion; improving pulmonary function including FEV1, FVC                                                                   [^83^](#jcph1644-bib-0083){ref-type="ref"}
  Sodium aescinate       10 mg/d; 14 d   COPD                              Inhibiting TNF‐α and IL‐6 in serum; improving pulmonary function including PaO~2~, PaCO~2~, FEV/FVC                     [^84^](#jcph1644-bib-0084){ref-type="ref"}, [^85^](#jcph1644-bib-0085){ref-type="ref"}
  β‐sodium aescinate    20  mg/d; 10 d   COPD                              Improving pulmonary function including FEV/FVC                                                                                                [^86^](#jcph1644-bib-0086){ref-type="ref"}
  Sodium aescinate       20 mg/d; 10 d   CPHD                              Reducing peripheral edema; improving pulmonary function including PaO~2~, PaCO~2~                                                             [^87^](#jcph1644-bib-0087){ref-type="ref"}

ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; CPHD, chronic pulmonary heart disease; FEV~1~, forced expiratory volume in 1 second; FiO~2~, fraction of inspiration O~2~, FVC, forced vital capacity; MMEF, maximum midexpiratory flow; MVV, maximum ventilatory volume PaCO~2~, arterial partial pressure of CO~2~; PaO~2~, arterial partial pressure of O~2~; PEF, peak expiratory flow; SARS, severe acute respiratory syndrome; SpO~2~, pulse oxygen saturation.
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Potential Role and Clinical Trials of Escin in the Management of COVID‐19 {#jcph1644-sec-0130}
=========================================================================

Potential Role of Escin in COVID‐19 {#jcph1644-sec-0140}
-----------------------------------

It is well known that SARS‐CoV and SARS‐CoV‐2 share very similar gene structure and clinical symptoms. RSV‐induced pneumonia and COVID‐19 pneumonia have some similar pathological changes. For example, they all have alveolar inflammatory exudation, inflammatory cell infiltration, and the formation of hyaline membrane. Dengue virus also shares some characteristics with COVID‐19, such as sudden onset of high fever and lymphocytopenia. The dosage of escin in clinic, that is, sodium aescinate injection, is until 20 mg/day, the blood concentration in vivo is estimated to reach the similar level as that in vitro. The characteristic of escin to inhibit the acute inflammation is similar to dexamethasone or methylprednisolone.[^74^](#jcph1644-bib-0074){ref-type="ref"}, [^88^](#jcph1644-bib-0088){ref-type="ref"} Psg has been a chemical warfare agent and can result in severe acute lung injury. In ALI induced by Psg, after latent stage of exposure, the burst inflammatory response is very similar to the cytokine storm in the late stage of COVID‐19. Proinflammatory cytokines TNF‐a, IL‐6, and IL‐8 are critical factors, and their concentrations are known to be altered in the process of ALI. TNF‐a, IL‐6, IL‐8, IL‐4, and IL‐10 levels were significantly increased in the serum and bronchoalveolar lavage fluid of Psg‐exposed rats. However, escin injection still could significantly decrease the mortality of rats resulting from phosgene.[^89^](#jcph1644-bib-0089){ref-type="ref"}, [^90^](#jcph1644-bib-0090){ref-type="ref"} Escin has shown that it could both attenuate ALI and inhibit the secretion of cytokines in animals and humans.

Escin is a traditional medicine that displays anti‐inflammatory, antiedematous and antioxidant properties, and has been widely used in the clinical treatment of traumatic edema, hemorrhoids, and chronic venous insufficiency,[^91^](#jcph1644-bib-0091){ref-type="ref"} without showing severe adverse reactions besides a few gastroenterological reactions for oral tablets and local reaction with injection.

Taking the effects of escin in vitro and in vivo, the pathophysiology and the inflammatory response in COVID‐19 into account, it can be deduced that escin may have a potential role to treat patients with COVID‐19 effectively, and it may be predicted that effective antiviral drugs, such as remdesivir, in combination with potent anti‐inflammatory drugs, such as escin, could have a possible therapeutic effects on the severe ALI of patients with COVID‐19.

Clinical Trials of Escin in COVID‐19 {#jcph1644-sec-0150}
------------------------------------

In China, a randomized, parallel, controlled trial for the efficacy and safety of sodium aescinate injection in the treatment of patients with COVID‐19 pneumonia is being conducted. The aim is to evaluate the efficacy and safety of sodium aescinate for injection compared with conventional treatment in patients with COVID‐19 and to compare the efficacy of conventional therapy plus sodium aescinate for injection and conventional therapy plus glucocorticoids. Chest imaging (computed tomography), C‐reactive protein, and IL‐6 plasma levels are used to evaluate the efficacy for patients with COVID‐19. In an Italian clinical trial, escin is administered to COVID‐19 patients as an oral formulation (40 mg 3 times daily) or injection (20 mg intravenously once daily) for 12 days, compared with standard treatment. Generally, a randomized, double‐blind, and parallel controlled trial is requested to evaluate the efficacy of the treatment and should be performed to reach scientific conclusion even if the treatment of patients with COVID‐19 pneumonia is urgent. Thus, the clinical trials in the future for COVID‐19 pneumonia need to be intensively designed.
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